Table 11 Adverse events in clinical trials of drug conjugates for lung cancer treatment
From: Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Drug name | Type | NCT number | Time frame | Number of AEs | All-cause mortality | Number of other AEs | Description |
|---|---|---|---|---|---|---|---|
Rova-T | ADC | NCT03543358 | Up to 13.6Â months | Not specified | 1 (33%) | 1 (33%) | Gastrointestinal disorders; psychiatric disorders |
TIVDAK | ADC | NCT03245736 | Day 1 to week 24 | 1 (20%) | 0 (0%) | 5 (100%) | Nervous system disorders |
TIVDAK | ADC | NCT02001623 | 1 to 249Â days | 6 (40%) | 1 (7%) | 15 (100%) | Nausea |